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Introduction
P53 is the most frequently altered tumor-suppressor gene in a wide spectrum of human tumors, including colon and breast carcinomas. P53 mutations occur in half of all malignancies, 1 often in late tumor progression. 2 Furthermore, other mechanisms such as up-regulation or amplification of genes such as mdm-2, binding to viral oncoproteins or nuclear exclusion 3, 4 might contribute to loss of wild-type (wt)p53 protein function.
The mechanisms underlying the biological activity of p53 indicate that the protein is involved in gene transcription, DNA synthesis and repair, genomic plasticity, and programmed cell death. 1 It has been reported that the p53 protein can act as a transcription factor 5, 6 that enhances the expression of specific genes containing p53-specific binding sequences in the vicinity of their promoters. 7 In normal cells DNA damage can induce p53 expression, which promotes G1 arrest or, apoptosis. 8 Loss of p53 functions, as occurs in cancer cells, causes loss of cell growth control and abrogation of the cell-death control exerted by wtp53. 9 Inactivation of wtp53 may also serve to fix stochastic mutations that allow rapid selection of 10 with a more aggressive phenotype 11, 12 and high proliferative activity. 13, 14 The reintroduction of wtp53 arrests cell growth in many transformed cells. [15] [16] [17] [18] [19] Indeed, transfected wtp53 gene expression triggers apoptosis in vitro, prevents colony formation in soft agar and inhibits tumor growth in nude mice. 20, 21 Established tumors in nude mice underwent regression upon wtp53 gene expression, following induction of apoptosis. [22] [23] [24] Introduction of wtp53 into metastatic p53-deficient cells resulted in terminal differentiation and apoptosis that inhibited the progressive growth of metastases in vivo. 25 Restoration of wtp53 presumably has different effects depending on both protein dosage 26, 27 and on cell type and degree of differentiation. 25, 28, 29 Indeed, each type of neoplastic cell offers a particular environment in which wtp53 might generate different effects. 30 Thus, if the different oncogene-activated pathways differentially modulate the suppressor functions of wtp53, the status of the endogenous p53 gene might also influence the effects of the exogenous gene. For example, reintroduction and overexpression of wtp53 into cells with mutated p53 lead to inhibition of cell growth but do not trigger programmed cell death or differentiation. 17 Consistent with this hypothesis, reintroduction of wtp53 into T47D and MDA-MB468 breast tumor cell lines was incompatible with the growth of these cells in vitro, whereas wtp53 expression in MCF-7 cells appeared to have no effect on cell growth. 15 The hemizygous state for p53 gene in T47D and MDA-MB 468 and the absence of p53 mutations in MCF-7 cells might account for this difference. 27 These observations suggest that differences in the effects promoted by exogenous wtp53 probably reflect the genetic characteristics of the recipient tumor cells. 31, 32 In breast cancer for example, several mutations are found in addition to those in the p53 gene and the individual contribution of each one in terms of growth advantage is still unclear. 33 We postulate that the expected benefits of restoration of wtp53 functions might also depend on genomic instability and on the extent of DNA damage that these cells have undergone. [34] [35] [36] Recent studies indicate that some cells might be able to develop certain resistance to tumor-suppressor genes, and that growth suppression and apoptosis might share a common signaling pathway. 37 In addition to this endogenous resistance, cells might resist the suppressive functions of exogenous wtp53 inducing mutations or losing the expression of the exogenous gene. To test this hypothesis, we stably transfected two cell lines with the full-length wtp53 gene and studied the integrity and the expression of the exogenous gene in the emerging clones. Cell lines were chosen on the basis of the differences in the status of the endogenous p53 gene: the MDA-MB 468 human breast cancer cell line which is hemizygous having a mutation in codon 273 in the remaining allele and the KM12 SM human colorectal-carcinoma cell line, which is heterozygous and has a mutation in codon 179 in one allele of the endogenous p53 gene.
Results
Transfection with wtp53: effects on proliferation in vitro To evaluate the role of exogenous wtp53, we transfected the MDA-MB468 breast carcinoma cell line (hemizygous for p53, containing a p53 mutation at codon 273 in the remaining allele) and the highly metastatic colon carcinoma cell line KM12SM (heterozygous for p53, containing a p53 mutation at codon 179 in one allele) with a cDNA wtp53. The full-length coding region of human wtp53 inserted into a mammalian expression vector pCDM8/neo 38 was used for transfection. In parallel, cells were transfected with the pCDM8/neo vector without p53 cDNA and used as negative control. Clones were first selected for geneticin (G418) resistance, then, cells were not propagated as a pool but were expanded clonally in media containing geneticin.
As shown in Table 1 , wtp53 induced a three-to four- fold decrease in colony number in both cell lines as compared with the control vector pCDM8/neo. This finding indicates that the suppression effect of the exogenous wtp53 was independent of the endogenous p53 status of the cell lines. Thus, it appears that exogenous p53 protein had an early detrimental effect on the growth of colonies following transfection, which confirmed previous observations made by others.
17
After 21 days of selection in medium containing G418, all single emergent colonies were expanded but only a few of them survived longer. A representative number of clones was examined for integration and expression of exogenous p53, as well as for their growth properties in vitro. Four of the 19 KM12-positive clones and six of the 13 positive MDA-MB 468 clones, were expanded and fully studied for the effects of exogenous wtp53. As shown in Figure 1 , several clones of MDA-MB 468 such as B6, grew more slowly than the clones obtained by transfection with control vector. These selected clones were maintained in culture for over 50 population doublings under the selective pressure of G418 in the medium and re-examined for growth rates in vitro. The differences between B6 and the other clones were not apparent until after 20 population doublings, indicating the possible loss of wtp53.
In contrast, we did not find any differences in proliferation in any individual clone of the KM12 transfectants either by 3 H-thymidine uptake or by SRB method (data not shown). We did not observe any differences either in saturation density or plating efficiency compared with the parental cells (data not shown). No difference was observed in the in vivo growth rate of tumors generated by KM12 SM-transfected clones compared with those developed by parental cells (data not shown).
The differences in tumor proliferation were evaluated in single individual tumors, and interestingly, staining with Ki-67 antigen showed a high proliferative activity in both wtp53 (60-70% in MDA p53 clones and 30-40% in KM12 p53 clones) and neotransfectants, without statistical differences (Figure 2a) . Our results show that the tumorigenic phenotype is not fully suppressed in mutated p53 cell lines that express exogenous wtp53 and survived longer.
Effect of exogenous wtp53 on apoptosis
To study whether the exogenous wtp53 induced apoptosis, we performed DNA fragmentation analysis on MDA-MB468-transfected cells and tumors. Nuclear DNA was extracted from cells soon after the clonal expansion in culture and then analyzed by agarose gel electrophoresis. The characteristic 'ladder' pattern of DNA was seen in clone B6 but was not detectable in those clones transfected with the vector alone (Figure 2b ). These data correlated well with the reduced growth rate observed at the same passage (Figure 1) , and also provide evidence that the p53-dependent apoptotic pathway is functional in MDA-MB 468 cells. Furthermore, they demonstrate that exogenous wtp53 mediated cell death mainly in MDA-MB 468 clone B6, indicating that these cells probably expressed wtp53 in early passages.
We also studied the apoptosis in tumor sections by in situ DNA fragmentation assay, which detects single apoptotic cells (Figure 2a ). We measured apoptosis in independent tumors arising from single clones inoculated into different animals. The percentage of apoptotic cells in tumors from wtp53 transfectant cells was low and similar, if not identical, in tumors of the parental cell lines or clones transfected with the vector alone in which apoptotic cells were Ͻ1%. Indeed, only in tumors arising from MDA p53 clone D3 (tumors F1 and D4) was the apoptotic ratio Ͼ3%.
Analysis of exogenous wtp53 in transfected cells
The presence of integrated vector DNA in the transfected clones was assessed by Southern blot hybridization, using the full-length human p53 cDNA as a probe. The results obtained with genomic DNA from the MDA-MB 468 parental cells and clones are shown in Figure 3 . A single XhoI fragment, which hybridized with the labeled probe, is shown in clones D3, D5 and D7 and has the same size as the original plasmid (1.27 kb) (Figure 3a) . After HindIII digestion, two bands, one of 5.7 and the other of 4.9 kb, corresponding to a fragment from the pCDM8/neo-p53 vector, were observed in the transfected clones B3 and B6, respectively ( Figure 4b ). The control DNA from non-transfected cells displayed two fragments (7.8 and 2.6 kb) after HindIII digestion (see the restriction map scheme in Figure 3 ). These results indicate that B3 and B6 clones had the vector integrated into the genome, and that clones D3, D5 and D7 also contained the exogenous gene wtp53.
In contrast, Figure 4 shows the Southern blot of wtp53 vector DNA in KM12SM cells. In this case, all DNA samples were digested with BglII, and a fragment of 8.7, 8.2, 5.4 or 4.1 kb was observed in KM12 transfectant clones D1, D6, G9 and G1, respectively. The results were confirmed by digestion with other restriction enzymes. The hybridization fragment diagnostic for the wtp53 vector DNA was found in clones B6, B3, B14 and B15 ( Figure 4c ) and in clones E3, E14 and G2 (data not shown) despite their ability to grow in the presence of 500 g/ml geneticin.
We then tested the integrity of the exogenous wtp53 by exon-specific PCR (Table 2 ) and sequence analysis (as described in Materials and methods). Genomic DNAs from early passages of in vitro cultured cells were extracted and analyzed. Southern blot analysis indicated that the exogenous wtp53 was often lost in both MDA-MB 468 and KM12 SM clones, whereas they continued to grow in the presence of geneticin. This finding demonstrated a strong selection of clones containing vector sequences which conferred geneticin resistance but did not ensure the integrity of the exogenous vector. Four of the six MDA-MB 468-transfected clones (B6, D3, D5 and D7) and only three of the four clones (D6, G1 and G9) of KM12SM-transfected cells retained the entire exogenous wtp53 gene.
Expression of the exogenous wtp53 gene
The results of the molecular analysis of p53 expression suggest that growth suppression in early passages in culture is mediated by high expression levels of exogenous wtp53 gene. The expression was assessed by Northern blot in early passages of both MDA-MB 468-and KM12 SM geneticin-resistant clones cultured in vitro. Whereas the exogenous gene was expressed in only three of the MDA-MB 468 clones (B6, D3 and D5) (Figure 5a ), it was expressed in all KM12 SM transfectants. Interestingly, the exogenous gene was detected in early passages of clone B6 as a faint band, but it was undetectable after several passages in vitro (see lane MDA p53 B6*). Exogenous wtp53 gene expression by clone D7 from MDA-MB 468 in early passages in vitro was also detected as a faint band. The endogenous gene was detected as a transcript of 1.8 kb, (Figure 5a and b) . The exogenous p53 mRNA is differentiated from endogenous mRNA by its size.
In addition, we explored whether the endogenous wtp53 gene was expressed in KM12 SM clones. The RT-PCR and direct sequencing consistently failed to identify any endogenous wtp53 in KM12 parental cells (Figure 6b ).
Because the exogenous wtp53 is truly expressed in KM12 D6 clone, as confirmed by Northern blot, we wondered why these cells failed to inhibit growth. The same question had arisen concerning MDA-MB 468 transfectants such as the clones D3 or D5. To address this issue, we performed the p53 functional assay in KM12 SM parental cells and the clones KM12p53 C6 and KM12p53 D6. The last one, which contains the exogenous wtp53, gave fewer red colonies (85%) than the parent or neo-transfected cells (97-98%). Sequencing of p53 cDNA from multiple red colonies given by clone D6 confirmed the presence of the same mutation as in parental cells. Furthermore, the increase in white colonies indicated the expression of the exogenous wtp53. Thus, in spite of wtp53 expression, the predominant phenotype was the mutated p53 originally present in KM12 SM cells.
Acquisition of new mutations in exogenous wtp53
The parental human breast carcinoma cell line MDA-MB 468 is hemizygous for the p53 gene and contains a single point mutation in the remaining allele at codon 273 (CGT → TGT). 15 On the other hand, the human colorectal carcinoma cell line KM12 SM is heterozygous for a mutation at codon 179 (ATG → GTG) of the p53 gene (Figure 6a) .
New mutations were detected in transfectants by PCR-SSCP. Figure 6a shows the PCR-SSCP of p53 mRNA results from MDA-MB 468 and KM12 SM cell lines, respectively. After sequencing the fragment, we confirmed the abnormalities observed in Figure 6a , which include codons 152-248. Indeed, MDA-MB 468 clones D3, D5 and D7 may contain a novel mutation. In contrast, no mobility shifts were detected in this fragment from KM12 SM clones D6, G1 or G9. Note that in this figure the p53 mRNA from MDA-MB 468 does not appear mutated because this fragment does not contain codon 273, which was originally mutated in this cell line.
To determine the structural alterations that caused the mobility shifts in the fragments described above, we subjected the PCR products to direct sequencing. Such alterations were identified as mutations and not as polymorphisms. The nucleotide sequences revealed novel mutations in the exogenous gene present in MDA-MB 468 clone D3, D5 and D7. Such a mutation has already been reported by Casey 15 in an emergent clone of MDA-MB 468 transfected with wtp53. Interestingly, we found novel mutations in a tumor xenograft from MDA-MB 468 clone B6, which were not found in early passages from the clone expanded in vitro (see Figure 7a, lane 1R4B6) . Furthermore, the tumor arose in an animal identified as 1R4 and contained a novel mutation localized in codon 154 that removes the HpaII site (Figure 7a ). To explore whether this was a specific mutational ability, we repeated the xenography in another group of animals, obtaining similar findings with additional mutations which occurred in vivo.
Three mutations appeared in a tumor xenograft identified as 2R5, which was also injected with B6 transfectants: one in codon 239 (see Figure 7b ) and two others in codons 272 and 273 (Figure 7c ). It is remarkable that these mutations were detected in the same tumor arising from one animal, while no mutations in the exogenous p53 gene were found in the remaining tumor xenografts from the same experiment. Interestingly, we studied different sections of the same tumor and it appeared that the mutation occurred in vivo, because we were able to identify the unmutated p53 in other tumor sections (see Figure 7c lane 2R5*B6).
Taken together, these results suggest that mutations may occur soon after selection of cell transfectants with G418 or even later, when they are grown as xenografts. This supports the hypothesis that wtp53 is an undesirable gene for those cells which develop novel mutations to abolish the growth inhibitory function of this protein. In contrast, no new mutations were detected in KM12-transfected clones with the wtp53 gene.
Discussion
The p53 gene is frequently rendered nonfunctional in human cancers by mutation or deletion. It is becoming, with increasing interest, a candidate gene for replacement by gene therapy. However, despite the promising results announced by recent clinical trials, the restoration of wild-type p53 gene function does not always result in tumor regression or inhibition of tumor growth. 39 The failure of this novel gene therapy has mainly been attributed to an incomplete targeting of the tumor cell population, but the impact of the endogenous p53 mutated protein and the genomic instability of the exogenous wtp53 gene should also be considered. 40 The results presented here indicate possible mechanisms to explain this failure in tumors. We transfected the wtp53 cDNA in two different cell lines in culture with known p53 status. The exogenous wtp53 is initially functional in our system, in so far as it induces cell growth inhibition and
Figure 6 Analyses of DNA fragments carrying the nucleotide sequence of codons 152-248 of the p53 gene. PCR-SSCP analysis of genomic DNA was performed as described in Materials and methods. PCR-SSCP demonstrated a mobility up-shift in D3, D5 and D7 transfectant clones relative to MDA-MB 468 parental cells and thereby, allowed identification of the exogenous p53 gene in the wtp53-transfectant clones at early passages growing in vitro. No mobility shift is demonstrated in MDA-MB 468 cells in (a), because the mutation was found in codon 273 (see c) which is not included in this PCR-SSCP fragment. A novel mutation acquired by the transfectant clone D3 is demonstrated by SSCP and sequencing ladder shown in (d). There was no mobility difference in KM12 transfectants compared with the controls. In (b) is shown the nucleotide sequence analysis of genomic and cDNA, indicating a single A to G point mutation at codon 179 in the KM12 SM parental cell line.
apoptosis in those cell clones that had integrated the exogenous cDNA. These findings strongly suggest that in our system, the exogenous wtp53 also has the suppressor functions as intended. However, several clones emerged and survived longer and tumors arising from these clones exhibited neither an increased cell proliferation nor a reduced apoptosis compared with those developed by parental cells. The failure of wtp53 to inhibit cell proliferation in our systems might be indicative of acting mechanisms that allow cells to escape the normal function of wtp53 on cell growth control. The results from the surviving cell clones suggest that the genome abrogates the exogenous wtp53 functions by the same mechanisms that inactivate the endogenous gene. To date, the possible mechanisms might include the abrogation of the normal function of exogenous gene by the endogenous mutated allele, the expression of truncated forms of p53 protein, insufficient levels of expression of wtp53, nuclear exclusion or simply mutation. A dominant negative effect exerted by the endogenous mp53 would presumably be acting in KM12 transfected cells according to results from functional assays, which also explains the reduced wtp53 function in these cells. However, different mechanisms might contribute to wtp53 failure. Indeed, the new mutations detected in these surviving clones account for the failure of exogenous wtp53 to reverse progression. Consistent with previous reports 15 we found several novel mutations in our MDA-MB 468 clones which expressed the exogenous p53 cDNA, indicating the importance of wtp53 inactivation for these cells. Furthermore, our results indicate that the inactivation of the exogenous p53 gene mainly occurs by mutation. Since mutations occur in the exogenous wtp53, we assume that this may be due to the mutator ability of MDA-MB 468 cells. In addition, our results suggest that this ability might somehow be directed to wtp53 which is essential to the suppression of the neoplastic phenotype of MDA-MB 468 cells.
To determine whether the mutations in the exogenous wtp53 gene were attributable to the genomic mutator mechanism lying in tumors, we analyzed the p53 status of several emerging cell clones. Indeed, several mutations were found in the exogenous wtp53 gene of some MDA-MB 468 clones, such as D3, D5 and D7, at early passages in vitro.
This finding suggests that mutations may occur quickly in this system, driven by the genome of these cells. Furthermore, the survivor clone B6 provides evidence of sequential changes in the exogenous wtp53. These changes in the foreign gene might be similar to those that occur spontaneously in tumor progression. It seems that the surviving clones lack the expression of wtp53 which is then mutated. Mutations occur both in vitro and in vivo and, furthermore, they might occur after several doubling times and not always at early stages. This result shows that mutations in the plasmidic p53 sequence occur after transfection and not in bacteria. Genes stably integrated into the genomes of somatic mammalian cells following transfection are integrated as tandemly duplicated DNA sequences. 41 Tandemly duplicated genes are unstable within the genomes of a variety of species. These sequences are subject to high mutation rates. 42 A similar
Figure 7 Detection of novel mutations acquired in xenografts. Mutations were detected in tumors arising from B6-transfectant cells inoculated in Balb/c nude mice. As can be seen in (a), a mutation was localized by RFLP analysis in xenograft 1R4 but not in 1R1tumor although both animals received the same cells growing in vitro. A single point mutation was identified in codon 154 (see right side of (a) compared with wtp53 plasmid DNA used as control. RFLP and SSCP analyses of DNA fragments carrying the nucleotide sequence of codons 152-248 of the p53 gene were performed as described in Materials and methods using genomic DNA from dissected tumors. PCR-SSCP demonstrated a mobility shift in 2R5 xenograft relative to wtp53 plasmid DNA, identified as a mutation in codon 239 (b). (d) illustrates the fragments obtained by HpaII endonuclease restriction enzyme of exon-specific PCR products (described in Materials and methods).
fact might also occur with our cells after integration of transfected DNA sequences. Then, once a mutation has arisen in a wtp53-transfected cell, the clonal selection occurs favoring the emergence of the malignant clone. 10, 43 A distinct mechanism to abrogate the function of the exogenous gene is the lack of expression by gene inactivation or simply gene loss. 42 The mechanism by which MDA-MB 468 cells escape from the growth-inhibitory function of wtp53 is the selective elimination of the p53 gene from the construct, even though the geneticin-resistance gene is retained because cells grow under selective pressure of G418. Our results with MDA-MB-468 clone B4 are the same as those obtained with A549 cells, 27 in which loss of expression was accompanied by the lack of exogenous wtp53 cDNA, because the B4 clone had partially lost the expression vector's sequence. This mechanism is also extremely efficient in KM12 SM cells because several clones lack the exogenous wtp53. Indeed, we did not detect the exogenous p53 gene in KM12 clones such as D1, E3, E14 and G2 in spite of their resistance to geneticin. These results indicate that the excision of these sequences may be a consequence of the unstable arrangement of transfected DNA sequences or due to the inherent instability in the genome of these cells. 44 Whether this instability should be attributed to the presence of an endogenous mutated p53 45 remains unclear. Furthermore, KM12 clone D6 which retained the exogenous wtp53 did not revert tumorigenicity or cell 
The presence of exon-specific PCR product is indicated as a +. We performed three different PCR using specific primers to amplify sequences corresponding to exons 2-6, exons 5-11 or exons 2-11 and products were visualized and size compared with that obtained with the vector p53 cDNA (pCDM8-p53(Arg)/neo used as control (as described in Materials and methods).
growth. Since the exogenous p53 gene was not mutated in this clone, the reason for the failure is not clear but might be related to the advanced malignancy of the cells which have many other genetic defects. On the other hand, KM12 SM cells contain one mutated allele and it was reported that mutant p53 proteins may affect transcriptional activation through interaction with wtp53. 46 thus altering its conformation. 47 Therefore, it is possible that in cells heterozygous for mutation in p53, the expression of the exogenous wtp53 may be inhibited by the oncogenic form of p53. Mutants of p53 have been found to be defective in various wtp53-related functions 48 and may also activate several promoters that could be involved in promoting cell proliferation. 49 Interestingly, in parental KM12 SM cells in which the wtp53 allele is maintained, we only detected the mutated allele by RT-PCR and direct sequencing of the product. This finding reinforces the results obtained with the functional assay for p53 and indicates that wtp53 may have varied effects on growth properties depending on p53 status and the cell-type recipient. Indeed, cells lacking wtp53 gene or its expression are more likely to respond to wtp53 reintroduction than others that retain the wtp53 15 and particularly those that express relatively high levels of wtp53 as well as mp53. 15 However, even in p53-null tumor cells it does not consistently produce the expected therapeutic effects. 50 The response may also be influenced by the extent of DNA damage and genome instability. 35, 51 In contrast, we did not find any evidence of instability in the microsatellite repeat sequences analyzed in MDA-MB 468 (data not shown), but this does not rule out other alternative mechanisms for genomic instability in these cells. In fact, loss of wtp53 removes an important negative constraint on neoplastic progression mainly attributed to the acquisition of genetic instability, 9, 12, 52 and an increase in homologous recombination, 53 as probably occurs in metastatic cells. 43 The failure of wtp53 gene to revert the malignant phenotype might be explained by such a mechanism in cells heterozygous for mutations in p53. Several potential clinical applications are expected for wtp53 therapy. Indeed, gene therapy with wtp53 has been found to be effective in inducing apoptosis and reversing the tumorigenicity in several human tumors growing in nude mice. 39, 54 However, we and others 50 have provided evidence that replacement of wtp53 gene in cells lacking endogenous p53 expression does not always restore normal growth or proliferation pathways. Consequently, this strategy must be genetically evaluated in each tumor before the expected benefits can be obtained. 40 In conclusion, our results show that cells are endowed with a specific machinery that may react against the exogenous wtp53 , abrogating its inhibitory-growth function with the purpose of assuring malignancy when it becomes compromised. This abrogation may be exerted through different mechanisms which might be related to those that originally inactivated the endogenous gene in each cell type.
Materials and methods

Cells and culture conditions
Human breast adenocarcinoma cells, MDA-MB-468, were obtained from American Type Culture Collection (Rockville, MD, USA). Human colon carcinoma cells, KM12SM, were obtained from Dr IJ Fidler (Cell Biology, MD Anderson, Houston, TX, USA). Cell lines were grown and maintained on plastic and incubated with 1:1 (v/v) mixture of Dulbecco's minimum essential medium (DMEM) and Ham's F12 medium (DMEM/F12) (GIBCO, BRL, Gaithersburg, MD, USA) supplemented with 10% heat inactivated fetal bovine serum (Biological Industries, Israel), pyruvate and l-glutamine in 5% CO 2 -95% air at 37°C in a humidified incubator. All cultures were found to be free of Mycoplasma contamination (Mycoplasma PCR Primer Set; Stratagene, La Jolla, CA, USA).
Plasmid and gene transfer
The pCDM8-p53 (Arg)/neo vector 38 was used to introduce the wtp53 cDNA into KM12SM and MDA-MB-468 cells. This vector contains the full-length coding region of the human p53 cDNA (1.3 kb, exons 2-11) under the transcriptional control of the cytomegalovirus (CMV) promoter. The plasmid, kindly provided by Dr Hideyuki Saya (Tumor Genetics and Biology, Kumamoto University, Japan), encodes a wild-type p53 with an arg at codon 72. The pCDM8/neo (Invitrogen, San Diego, CA, USA) vector was used as a transfection control.
MDA-MB-468 and KM12SM cells were seeded at a density of 5 × 10 5 and 2.5 × 10 5 cells per 100-mm dish, respectively and transfected with Lipofectin reagent (GIBCO BRL) with 5 g of vector pCDM8-p53 (arg)/neo or pCDM8/neo according to the manufacturer's specifications. Stable transfectants were selected with 500 g/ml of G418 in media. After 15-21 days of selection the total number of colonies arising was determined and G418-resistant colonies were individually plated into a 2 cm 2 well and then expanded.
Integration and integrity analysis Genomic DNAs were extracted from individually transfected clones. Briefly, pellets of 10 7 cells were collected, 31 washed in cold PBS and lysed in a solution containing 10 mm Tris-HCl pH 7.8, 5 mm EDTA, 0.5% SDS, 300 g/ml RNase A and 200 g/ml Proteinase K, at 37°C for 16 h. High molecular weight DNA was purified by serial phenol-chloroform extractions and ethanol precipitation.
Ten micrograms of DNA were digested with HindIII, XhoI or BglII restriction enzyme (Boehringer Mannheim, Mannheim, Germany), and then separated by electrophoresis on 0.8% agarose gels and transferred to nylon membrane Biodyne A (Pall Industrie, Saint Germain-en laye, France) according to the Southern procedure. Hybridization was performed with Rapid-hyb buffer at 65°C for 2 h 30 min (Amersham, Bucks, UK) using as a probe the full-length human p53 cDNA. The probe was labeled with ␣ 32 P-dCTP by random priming using the Prime-it II labeling kit (Stratagene). Membranes were washed under high stringency conditions in 0.1 × SSC, 0.1% SDS at 65°C, and exposed to radiographic films.
The acquisition of exogenous p53 cDNA and its integrity were determined using total DNA extracted from independent clones growing in vitro at early passages. Four PCR reactions were performed to determine the integrity of exogenous p53 gene directed to amplify the regions of p53 cDNA between exons 2-6, exons 5-11 or the entire region including exons 2-11. Briefly, 100 ng of DNA was added to an Eppendorf containing 1 unit of Taq Briefly, PCR including exons 2-11 was performed in two steps: the first PCR with the primers (−5U) and (394D); the second, nested PCR, was performed with 0.5 l of the previous reaction with the primers (−1U) and (380D) under the same conditions as described above.
Mutation detection
The presence of mutations in the endogenous and exogenous p53 genes was analyzed by SSCP and RFLP method and direct sequencing of PCR products. We used the product of the PCR including exons 2-11 as a template. A nested PCR was then performed using 1 l of 1:1000-fold dilution of these products and the specific primers 126U and 331DB2. The PCR reaction included the radioactive nucleotide ␣ 32 P-dCTP (Amersham). Five microlites of the PCR product was digested with HpaII restriction enzyme and electrophoresed on a 6% polyacrylamide nondenaturing sequencing gel with and without 10% glycerol at room temperature at 30 W for 12 min and 6 W for 14 h or 5 h, respectively.
The mutations in the endogenous p53 gene were detected using p53 cDNA generated by RT-PCR. 51 The RT reaction was performed using 0. The sequences of primers were as follows:
The presence of the mutation was confirmed by sequencing the PCR products using a commercial cycle sequencing kit (Ampli cycle, Perkin Elmer, Roche Molec Systems, Branchburg, NJ, USA) according to the manufacturer's recommendations and including ␣ 32 P-d CTP. The sequencing reaction was performed by 30 cycles in the same conditions as for PCR amplification. The final product was diluted two-fold in formamide-dye loading buffer. Sample was denatured for 3 min at 95°C and cooled on ice, and 2 l was analyzed in a denaturing 6% polyacrylamide/8M urea sequencing gel for 2-5 h at 55 W.
Analysis of of p53 expression mRNA was extracted from cells growing in culture using poly-A-Track System 1000 isolation kit according to the manufacturer's instructions (Promega, Madison, WI, USA). Briefly, 12 g poly(A)-containing RNA was electrophoresed on 1.1% agarose gel in denaturing conditions and blotted on to a Qiabrane nylon plus membrane (Qiagen, Chatsworth, CA, USA). Filters were hybridized with the full-length human p53 cDNA. The probe was radiolabeled using the random primer technique with ␣-32 P-d CTP. Hybridization was carried out at 42°C overnight and the filters were washed to a final stringency of 0.1 × SSC and 0.1% SDS at 55°C. After hybridization with the full-length human p53 cDNA, the filters were stripped and rehybridized with ␤-actin probe as a loading control.
P53 functional assay in which yeast change color according to p53 status, was performed using mRNA from parental KM12 SM cells, neo-transfectant and clone D6 transfected with wtp53, as described by Flaman et al. 55 cDNA was synthesized by RT-PCR as described above and using the RT1 primer 5′-CGC GAG GTA GAC-3′.
PCR for amplification of exons 4-11 was performed with primers 5′-GTT CTG TCC CCC TTG CCG TCC CAA GAC ATG-3′ and 5′-CAG TCT ACC TCC CGC CAT AAA AAA CTA-3′. After PCR, 5 l of the product was checked by gel electrophoresis and 5 l was used directly for yeast transformation. yIG397 was cultured in complete medium supplemented with adenine (200 g/ml). Yeast was cotransformed with unpurified PCR product, linearized vector pSS16 and carrier DNA by the lithium acetate procedure, and then plated on to synthetic minimal medium minus leucine plus adenine (5 g/ml), and incubated for 2-3 days at 37°C. Colonies containing wtp53 were white (ADE2 + ) and colonies containing mutant p53 were red (ade2 − ). Red colonies were scored after 2 more days of incubation at 4°C.
Cell proliferation analysis
Cell proliferation in vitro was estimated by a colorimetric method 56 for measuring the cellular protein content of adherent cultures. Briefly, 5 × 10 3 cells were seeded in a 96-well microtiter plate and were fed with complete medium, as described previously. After 24, 48 and 72 h the cell cultures were washed twice in PBS and cells were fixed with trichloroacetic acid and stained for 30 min with 0.4% (w/v) sulforhodamine B (SRB) dissolved in 1% acetic acid. Unbound dye was removed by four washes in 1% acetic acid, and protein-bound dye was extracted with 10 mm unbuffered Tris base and measured in a 96-well microtiter plate reader at 510 nm. Each time-point was performed in quintuplicate, and the background (complete medium) was substracted.
Tumor proliferation was evaluated in frozen sections of tumor tissues by IHC staining, using anti-Ki-67 monoclonal antibody (Clone MIB-1; Immunotech, Marseille, France). Bound antibody was visualized with biotinylated goat anti-mouse IgG (Vector Laboratories, Burlingame, CA, USA). Vectastain ABC kit (Vector) was used to amplify the signal following visualization with diaminobencidine substrate and counterstaining with hematoxylin. Cells with nuclear staining were considered positive and scored in four different fields at ×60 magnification.
Tumorigenicity
Athymic Balb/c nude mice were obtained from the Animal Production Area of Iffa Credo (Lyon, France). The mice were maintained in pathogen-free conditions and used when they were 5 weeks old. For MDA-MB-468 xenografts 2 × 10 6 cells embedded with matrigel 57 were inoculated into intra-mammary fat pad (i.m.f.p.) of female mice. For KM12SM xenografts 2 × 10 6 cells were inoculated subcutaneously in male mice. Tumor volumes were calculated from caliper measurements of two orthogonal diameters (x and y, larger and smaller diameters, respectively) by using the formula volume = xy 2 /2. Five mice were used per group in each of two independent experiments. The growth was monitored for 3-4 months. When tumors reached 1 cm 3 , the animals were killed and tumors were dissected, harvested and immediately frozen. All procedures and animal care were carried out in accordance with Institutional guidelines.
DNA fragmentation assay and detection of apoptotic nuclei DNA fragmentation was analyzed by the procedure described previously. 58 Briefly, 2 × 10 6 cells from each clone were washed twice in phosphate-buffered saline and then lysed in hypotonic detergent buffer (10 mm Tris-HCl, pH 7.5, 1 mM EDTA, 0.2% Triton X-100) for 30 min at 4°C. Cell organelles were removed by centrifugation at 12 000 g for 20 min, and the DNA was extracted by phenol-chloroform following treatment with RNase A (75 g/ml) and 200 g/ml Proteinase K as described previously. The DNA present in the aqueous phase was precipitated with NaCl (300 mm final concentration) and two volumes of ethanol at −20°C overnight. Pellets were washed in 70% (v/v) ethanol and then resuspended in 10 mm Tris-HCl, pH 8.0, 0.1 mm EDTA. Aliquots were analyzed by electrophoresis on 1% agarose gels in 1 × TBE buffer. DNA was visualized after ethidium bromide staining.
Apoptosis was detected histologically in frozen sections of primary tumors by TUNEL, 59 using 0.3 enzyme units/l terminal deoxynucleotidyl transferase and its buffer (Boehringer Mannheim) with biotinylated poly dU (dUTP). Nuclei were visualized with ABC complex followed by DBA staining and counterstaining with hematoxylin.
